Eber E, Trawinska-Bartnicka M, Sands D, et al. - Given that lancovutide, a polycyclic peptide derived from Streptomyces cinnamoneous, activates a chloride channel (TMEM-16A) other than the cystic fibrosis (CF) transmembrane conductance regulator protein and could benefit CF patients, researchers conducted this randomized, controlled trial was to test the effectiveness and safety of three different lancovutide treatment regimens vs placebo in a larger trial over a longer treatment period (8 weeks). One hundred sixty-one patients ≥ 12 years with a confirmed diagnosis of CF were randomized to either placebo (saline) or active drug in 3 different dosing schemes of 2.5 mg inhaled lancovutide (once daily, every other day or twice a week) for eight weeks. Compared with placebo, lancovutide did not improve forced expiratory volume in 1 second percent predicted. Overall, lancovutide's safety and tolerability were acceptable.